MDS Inc.'s Corporate Profile
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company with US$1.1 billion in net revenues that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of analytical instruments, medical isotopes for molecular imaging, radiotherapeutics and sterilization technologies and pharmaceutical contract research. MDS products and services reach people in more than 62 countries around the world with 95 percent of revenues from global markets.
MDS continues to make changes to strengthen the company's position as a leading innovator in global life sciences markets. The company is executing a growth strategy that focuses exclusively on opportunities within the fast growing life sciences markets served by the company's three core businesses:
- MDS Analytical Technologies is a leading innovator in providing products, services and new tools that support drug discovery and development and analytical measurement. It operates in an estimated U.S.$6 billion market with 6-10 percent growth rates.
- MDS Nordion is a world leader in providing innovative technologies for use in medical imaging, targeted cancer treatments, and sterilization of medical products. It operates in an estimated U.S.$4 billion market that is growing 5-7 percent a year.
- MDS Pharma Services is a leading contract research organization that provides both early stage and late stage drug discovery and development services to pharmaceutical and biotech companies through 39 sites in 29 countries around the world. It operates in an estimated U.S.$15 billion market that is growing 10-13 percent annually.
MDS was founded in 1969 and now has more than 5,500 highly skilled people operating in 29 countries.
MDS trades on the Toronto Stock Exchange (TSX: MDS) and on the New York Stock Exchange (NYSE: MDZ). MDS is part of the S&P/TSX 60 and the S&P/TSX Capped Health Care Index.
We welcome questions from our investors and shareholders. For general investor information, please call our automated MDS Shareholder Communication Service at 1 888 MDS 7222 in North America.
For specific inquiries, we invite you to contact Kim Lee, Senior Director, Investor Relations, MDS Inc.
Tel: +1 416 213 4721
Email: kim.lee@mdsinc.com
MDS Inc.
2700 Matheson Blvd. East
Suite 300, West Tower
Mississauga, Ontario
L4W 4V9
Canada
 Back to Top
|
